TOKYO -- Japanese drugmaker Eisai will apply for regulatory approval in the U.S. for preventative use of its Alzheimer's drug lecanemab as soon as the fiscal year starting April 2026.
Pharmaceuticals
Eisai seeks expanded use of Alzheimer's drug for prevention
Leqembi in final trial as Japan drugmaker plans 2026 application for U.S. approval
If lecanemab proves safe and effective as a preventative treatment for Alzheimer's disease, it could help to lower medical and nursing care costs around the world.
Read Next
Latest on Pharmaceuticals
